Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone
NCT ID: NCT06865365
Last Updated: 2025-03-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE4
72 participants
INTERVENTIONAL
2025-05-01
2028-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy
NCT04883346
Saxenda in Obesity Services (STRIVE Study)
NCT03036800
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
NCT03480022
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
NCT00422058
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
NCT02963922
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After one year, the investigator will also check whether the weight loss has been maintained and whether the preoperative Saxenda continues to lose even more weight after the operation.
All patients looking for bariatric surgery with health insurance via Österreichische Gesundheitsklasse and BMI\>35kg/m2 will be asked to take part in this study.
Patients with previous bariatric surgeries or contraindications against liraglutide will be excluded from this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A - Control Group with only dietological measures
Patients seeking bariatricsurgery will recieve the standard dietological measures to prepare for bariatric surgery for 6 months
Dietologic measures and lifestyle optimization for weight loss
all subjects will receive dietary measures and lifestyle opitmization suggestions in order to drop weight preoperatively.
Group B - Intervention with additional Liraglutide
Patients seeking bariatricsurgery will recieve the standard dietological measures and additional Liraglutide to prepare for bariatric surgery for 6 months
Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions
Liraglutide daily (0.6-3.0mg, highest tolerable dose) as additional preoperative method for weight loss
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions
Liraglutide daily (0.6-3.0mg, highest tolerable dose) as additional preoperative method for weight loss
Dietologic measures and lifestyle optimization for weight loss
all subjects will receive dietary measures and lifestyle opitmization suggestions in order to drop weight preoperatively.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI \> 35.0 kg/m2
* Health insurance via Österreichische Gesundheitskasse
* Willingness to be assigned to either of the two groups
* Willingness to adhere to preoperative dietological measures
* Follow-up anticipation with blood draws and body weight scans using Secca scale
* Written informed consent
Exclusion Criteria
* Patients aged below 18 years
* Patients with BMI \< 35 kg/m2
* Patients with psychiatric disorders
* Patients not willing to adhere to preoperative dietological measures
* Patients with contraindications against Saxenda
* Patients who have health insurance other than Österreichische Gesundheitskasse
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daniel Moritz Felsenreich
Professor (Ap. Prof. Priv. Doz. DDr. )
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2493/2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.